석기태 교수
전문진료분야
간염, 지방간, 간경변, 간암, 치료내시경, 고주파 열치료
전화 예약
033) 240-5000
기본정보
학력
2008.09 ~ 2010.08연세대학교 의학 박사 1993.03 ~ 1999.02연세대학교 원주캠퍼스 의학 학사 2001.03 ~ 2003.02연세대학교 내과 석사 |
경력
現 한림대학교춘천성심병원 소화기내과 과장 現 한림대학교 의과대학 내과학 교수 2014 ~ 2016Post-Doc Research Scholar, Department of Medicine, Columbia University, NY, USA Toranomon hospital (Tokyo) 단기방문교수 2007 ~ 2009연세대학교 원주세브란스기독병원 연구강사 및 임상조교수 2004 ~ 2006이라크 자이툰 병원 내과과장 1999 ~ 2004연세대학교 원주세브란스기독병원 수련의 및 전공의 |
학회활동
임상초음파학회 평생회원 대한 소화기항암학회 정회원 대한 Helicobacter 및 상부위장관 연구학회 평생회원 대한 내과학회 평생회원 대한 소화기내시경학회 평생회원 대한 소화기학회 정회원 대한 간학회 평생회원 |
수상이력
Marquis Who's Who (2018) Liver Week Best Presentation (2017) 세계인명사전 Marquis Who's Who 2016 등재 Liver Week 대한간학회 GSK 학술논문상 (2016) Liver week 우수발표상 (2012) 최우수발표상 (2014) 장연구학회 우수연제상 (2009) 소화기내시경학회 월봉학술상 대상 (2008) 대한 Helicobacter 및 상부위장관 연구학회 우수상 (2008) |
논문
1. Sharma SP, Gupta H, Kwon GH, Lee SY, Song SH, Kim JS, Park JH, Kim MJ, Yang DH, Park H, Won SM, Jeong JJ, Oh KK, Eom JA, Lee KJ, Yoon SJ, Ham YL, Baik GH, Kim DJ, Suk KT. Clin Mol Hepatol. 2024 Jul 25. Gut microbiome and metabolome signatures in liver cirrhosis-related complications
2. Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease. Park IG, Yoon SJ, Won SM, Oh KK, Hyun JY, Suk KT, Lee U. Sci Rep. 2024 Jul 12;14(1):16122.
3. A scheme to underpin key mediator(s) in Salinosporamide(s) against pan-tumor via systems biology concept. Oh KK, Yoon SJ, Song SH, Park JH, Kim JS, Kim MJ, Kim DJ, Suk KT. J Transl Med. 2024 May 24;22(1):492.
4. The synchronized feature of Saururus chinensis and gut microbiota against T2DM, NAFLD, obesity and hypertension via integrated pharmacology. Oh KK, Yoon SJ, Song SH, Park JH, Kim JS, Kim DJ, Suk KT. Artif Cells Nanomed Biotechnol. 2024 Dec;52(1):278-290.
5. A consortium of Hordeum vulgare and gut microbiota against non-alcoholic fatty liver disease via data-driven analysis. Lee SB, Gupta H, Min BH, Ganesan R, Sharma SP, Won SM, Jeong JJ, Cha MG, Kwon GH, Jeong MK, Hyun JY, Eom JA, Park HJ, Yoon SJ, Lee SY, Choi MR, Kim DJ, Oh KK, Suk KT. Artif Cells Nanomed Biotechnol. 2024 Dec;52(1):250-260
6. New insight of chemical constituents in Persea americana fruit against obesity via integrated pharmacology. Cha MG, Lee SB, Yoon SJ, Lee SY, Gupta H, Ganesan R, Sharma SP, Won SM, Jeong JJ, Kim DJ, Oh KK, Suk KT. Clin Transl Sci. 2024 Mar;17(3):e13778.
7. The epitome of tailor-made short positively charged peptides against HCC via integrated pharmacology. Oh KK, Eom JA, Lee KJ, Kwon GH, Yoon SJ, Song SH, Park JH, Kim JS, Kim DJ, Suk KT. J Transl Med. 2024 Mar 15;22(1):279
8. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation. Min BH, Devi S, Kwon GH, Gupta H, Jeong JJ, Sharma SP, Won SM, Oh KK, Yoon SJ, Park HJ, Eom JA, Jeong MK, Hyun JY, Stalin N, Park TS, Choi J, Lee DY, Han SH, Kim DJ, Suk KT. Gut Microbes. 2024 Jan-Dec;16(1):2307568.
9. Gut-microbiota prompt activation of natural killer cell on alcoholic liver disease. Eom JA, Jeong JJ, Han SH, Kwon GH, Lee KJ, Gupta H, Sharma SP, Won SM, Oh KK, Yoon SJ, Joung HC, Kim KH, Kim DJ, Suk KT. Gut Microbes. 2023 Dec;15(2):2281014.
10. Lee NY, Shin MJ, Youn GS, Yoon SJ, Choi YR, Kim HS, Gupta H, Han SH, Kim BK, Lee DY, Park TS, Sung H, Kim BY, Suk KT. Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. Clin Mol Hepatol. 2021 Jan;27(1):110-124. doi: 10.3350/cmh.2020.0125. Epub 2020 Dec 3.
11. Lee NY, Joung HC, Kim BK, Kim BY, Park TS, Suk KT. et al. Lactobacillus lactis CKDB001 ameliorate progression of nonalcoholic fatty liver disease through of gut microbiome: addendum. Gut Microbes. 2020 Nov 9;12(1):1829449. doi: 10.1080/19490976.2020.1829449.
12. Lee NY, Yoon SJ, Han DH, Gupta H, Youn GS, Shin MJ, Ham YL, Kwak MJ, Kim BY, Yu JS, Lee DY, Park TS, Park SH, Kim BK, Joung HC, Choi IS, Hong JT, Kim DJ, Han SH, Suk KT. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes. 2020 Jan 22:1-18. doi: 10.1080/19490976.2020.1712984.
13. Suk KT, Yoon JH, Kim MY, Kim CW, Kim JK, Park H, Hwang SG, Kim DJ, Lee BS, Lee SH, Kim HS, Jang JY, Lee CH, Kim BS, Jang YO, Cho MY, Jung ES, Kim YM, Bae SH, Baik SK Transplantation with Autologous Bone Marrow-Derived Mesenchymal Stem Cells for Alcoholic Cirrhosis: Phase 2 Trial Hepatology.2016; 64(6):2185
14. Suk KT, Mederacke I, Gwak GY, Cho SW, Adeyemi A, Friedman R, Schwabe RF. Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. Gut. 2016; 65(10):1721-32
2. Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease. Park IG, Yoon SJ, Won SM, Oh KK, Hyun JY, Suk KT, Lee U. Sci Rep. 2024 Jul 12;14(1):16122.
3. A scheme to underpin key mediator(s) in Salinosporamide(s) against pan-tumor via systems biology concept. Oh KK, Yoon SJ, Song SH, Park JH, Kim JS, Kim MJ, Kim DJ, Suk KT. J Transl Med. 2024 May 24;22(1):492.
4. The synchronized feature of Saururus chinensis and gut microbiota against T2DM, NAFLD, obesity and hypertension via integrated pharmacology. Oh KK, Yoon SJ, Song SH, Park JH, Kim JS, Kim DJ, Suk KT. Artif Cells Nanomed Biotechnol. 2024 Dec;52(1):278-290.
5. A consortium of Hordeum vulgare and gut microbiota against non-alcoholic fatty liver disease via data-driven analysis. Lee SB, Gupta H, Min BH, Ganesan R, Sharma SP, Won SM, Jeong JJ, Cha MG, Kwon GH, Jeong MK, Hyun JY, Eom JA, Park HJ, Yoon SJ, Lee SY, Choi MR, Kim DJ, Oh KK, Suk KT. Artif Cells Nanomed Biotechnol. 2024 Dec;52(1):250-260
6. New insight of chemical constituents in Persea americana fruit against obesity via integrated pharmacology. Cha MG, Lee SB, Yoon SJ, Lee SY, Gupta H, Ganesan R, Sharma SP, Won SM, Jeong JJ, Kim DJ, Oh KK, Suk KT. Clin Transl Sci. 2024 Mar;17(3):e13778.
7. The epitome of tailor-made short positively charged peptides against HCC via integrated pharmacology. Oh KK, Eom JA, Lee KJ, Kwon GH, Yoon SJ, Song SH, Park JH, Kim JS, Kim DJ, Suk KT. J Transl Med. 2024 Mar 15;22(1):279
8. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation. Min BH, Devi S, Kwon GH, Gupta H, Jeong JJ, Sharma SP, Won SM, Oh KK, Yoon SJ, Park HJ, Eom JA, Jeong MK, Hyun JY, Stalin N, Park TS, Choi J, Lee DY, Han SH, Kim DJ, Suk KT. Gut Microbes. 2024 Jan-Dec;16(1):2307568.
9. Gut-microbiota prompt activation of natural killer cell on alcoholic liver disease. Eom JA, Jeong JJ, Han SH, Kwon GH, Lee KJ, Gupta H, Sharma SP, Won SM, Oh KK, Yoon SJ, Joung HC, Kim KH, Kim DJ, Suk KT. Gut Microbes. 2023 Dec;15(2):2281014.
10. Lee NY, Shin MJ, Youn GS, Yoon SJ, Choi YR, Kim HS, Gupta H, Han SH, Kim BK, Lee DY, Park TS, Sung H, Kim BY, Suk KT. Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. Clin Mol Hepatol. 2021 Jan;27(1):110-124. doi: 10.3350/cmh.2020.0125. Epub 2020 Dec 3.
11. Lee NY, Joung HC, Kim BK, Kim BY, Park TS, Suk KT. et al. Lactobacillus lactis CKDB001 ameliorate progression of nonalcoholic fatty liver disease through of gut microbiome: addendum. Gut Microbes. 2020 Nov 9;12(1):1829449. doi: 10.1080/19490976.2020.1829449.
12. Lee NY, Yoon SJ, Han DH, Gupta H, Youn GS, Shin MJ, Ham YL, Kwak MJ, Kim BY, Yu JS, Lee DY, Park TS, Park SH, Kim BK, Joung HC, Choi IS, Hong JT, Kim DJ, Han SH, Suk KT. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes. 2020 Jan 22:1-18. doi: 10.1080/19490976.2020.1712984.
13. Suk KT, Yoon JH, Kim MY, Kim CW, Kim JK, Park H, Hwang SG, Kim DJ, Lee BS, Lee SH, Kim HS, Jang JY, Lee CH, Kim BS, Jang YO, Cho MY, Jung ES, Kim YM, Bae SH, Baik SK Transplantation with Autologous Bone Marrow-Derived Mesenchymal Stem Cells for Alcoholic Cirrhosis: Phase 2 Trial Hepatology.2016; 64(6):2185
14. Suk KT, Mederacke I, Gwak GY, Cho SW, Adeyemi A, Friedman R, Schwabe RF. Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis. Gut. 2016; 65(10):1721-32